Skip to main content

Table 1 Characteristics of ART-naïve and ZDVm-experienced women when starting therapeutic ART in 2000-2009

From: Response to antiretroviral therapy (ART): comparing women with previous use of zidovudine monotherapy (ZDVm) in pregnancy with ART naïve women

Demographic and clinical characteristics at start of therapeutic ART ZDVm-experienced (n = 91) ART-naïve (n = 1937) p-value
Age (years), median (IQR) 33 (30–37) 35 (30–40) 0.01
Time since HIV diagnosis (years), median (IQR) 5 (4–9) 4 (2–7) <0.001
Pregnant, n (%) 27 (29.7) 147 (7.6) <0.001
Ethnicity, n (%) Black 67 (73.6) 1349 (69.6) 0.42
Non-black/not known 24 (26.4) 588 (30.3)  
Risk group, n (%) Heterosexual sex 89 (97.8) 1718 (88.7) 0.006
Other 2 (2.2) 219 (11.3)  
Year, n (%) 2000-2002 13 (14.3) 375 (19.4) 0.40
2003-2005 32 (35.1) 589 (30.4)  
2006-2009 46 (50.6) 973 (50.2)  
ART regimen started, n (%)      
PI based (boosted and non-boosted) 22 (24.2) 552 (28.5) 0.48
NNRTI 57 (62.6) 1192 (61.5)  
NRTI/other 12 (13.2) 193 (10.0)  
Baseline CD4 count Median (IQR), (cells/mm3) 226 (162–339) 225 (150–304) 0.16
(n = 75, n = 1431) CD4 <200 cells/mm3, n (%) 29 (38.7) 584 (40.8) 0.71
CD4 <350 cells/mm3, n (%) 57 (76.0) 1195 (83.5) 0.09
Baseline viral load Median (IQR), (log10 copies/ml) 4.1 (3.2-4.5) 4.3 (3.4-4.9) 0.08
(n = 68, n = 1371) ≤50 copies/ml, n (%) 4 (5.9) 126 (9.2) 0.35
≤400 copies/ml, n (%) 8 (11.8) 228 (16.6) 0.29
≤10,000 copies/ml, n (%) 28 (41.2) 535 (39.0) 0.72
Hepatitis C co-infection, n (%) 4 (4.4) 170 (8.8) 0.14
Hepatitis B co-infection, n (%) 1 (1.1) 55 (2.8) 0.32
Previous AIDS event, n (%) 7 (7.7) 279 (14.4) 0.07
  1. IQR, Interquartile range; PI, protease inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor.